SILO PHARMA, INC. Stock-Based Compensation
SILO PHARMA, INC. (SILO) reported Stock-Based Compensation of $95.79 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- SILO PHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $39.17K.
- SILO PHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $56.62K, a 68.28% decline year-over-year.
- SILO PHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $52.31K, a 86.77% decline year-over-year.
- SILO PHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $47.27K, a 72.15% decline year-over-year.
- SILO PHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $906.77K, a 4.03% increase from fiscal 2023.
- SILO PHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $871.63K, a 50.89% increase from fiscal 2022.
- SILO PHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $577.65K, a 46.20% increase from fiscal 2021.
- SILO PHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2021 was $395.12K, a 47.73% decline from fiscal 2020.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 15 month | Share-based Payment Arrangement, Noncash Expense 18 month | Share-based Payment Arrangement, Noncash Expense 21 month | Share-based Payment Arrangement, Noncash Expense 24 month | Share-based Payment Arrangement, Noncash Expense 27 month | Share-based Payment Arrangement, Noncash Expense 30 month | Share-based Payment Arrangement, Noncash Expense 33 month | Share-based Payment Arrangement, Noncash Expense 36 month | Share-based Payment Arrangement, Noncash Expense 39 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $39.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $95.79K 10-Q · filed 2026-08-13 | $148.10K derived: sum of 3 quarters · filed 2026-08-13 | $195.37K derived: sum of 4 quarters · filed 2026-08-13 | |||||||||
| 2026-03-31 | $56.62K 10-Q · filed 2026-05-14 | $108.93K derived: sum of 2 quarters · filed 2026-05-14 | $156.19K derived: sum of 3 quarters · filed 2026-05-14 | -$4.83K derived: sum of 4 quarters · filed 2026-08-13 | |||||||||
| 2025-12-31 | $52.31K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $99.58K derived: sum of 2 quarters · filed 2026-04-14 | -$61.45K derived: sum of 3 quarters · filed 2026-08-13 | $117.02K POS AM · filed 2026-04-14 | |||||||||
| 2025-09-30 | $47.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$113.76K derived: sum of 2 quarters · filed 2026-08-13 | $64.71K 10-Q · filed 2025-11-13 | $460.02K derived: sum of 4 quarters · filed 2026-08-13 | |||||||||
| 2025-06-30 | -$161.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $17.45K 10-Q · filed 2026-08-13 | $412.75K derived: sum of 3 quarters · filed 2026-08-13 | $582.49K derived: sum of 4 quarters · filed 2026-08-13 | |||||||||
| 2025-03-31 | $178.47K 10-Q · filed 2025-05-09 | $573.78K derived: sum of 2 quarters · filed 2025-05-09 | $743.51K derived: sum of 3 quarters · filed 2025-05-09 | $911.90K derived: sum of 4 quarters · filed 2025-05-09 | |||||||||
| 2024-12-31 | $395.31K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $565.05K derived: sum of 2 quarters · filed 2025-03-28 | $733.43K derived: sum of 3 quarters · filed 2025-03-28 | $906.77K 10-K · filed 2025-03-28 | |||||||||
| 2024-09-30 | $169.74K 10-Q · filed 2024-11-12 | $338.12K derived: sum of 2 quarters · filed 2024-11-12 | $511.46K 10-Q · filed 2024-11-12 | $672.35K derived: sum of 4 quarters · filed 2025-05-09 | |||||||||
| 2024-06-30 | $168.38K 10-Q · filed 2024-08-13 | $341.73K 10-Q · filed 2024-08-13 | $502.62K derived: sum of 3 quarters · filed 2025-05-09 | $881.91K derived: sum of 4 quarters · filed 2025-05-09 | |||||||||
| 2024-03-31 | $173.35K 10-Q · filed 2025-05-09 | $334.23K derived: sum of 2 quarters · filed 2025-05-09 | $713.53K derived: sum of 3 quarters · filed 2025-05-09 | $882.71K derived: sum of 4 quarters · filed 2025-05-09 | |||||||||
| 2023-12-31 | $160.89K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $540.18K derived: sum of 2 quarters · filed 2025-03-28 | $709.37K derived: sum of 3 quarters · filed 2025-03-28 | $871.63K 10-K · filed 2025-03-28 | |||||||||
| 2023-09-30 | $379.29K 10-Q · filed 2024-11-12 | $548.48K derived: sum of 2 quarters · filed 2024-11-12 | $710.74K 10-Q · filed 2024-11-12 | $964.47K derived: sum of 4 quarters · filed 2024-11-12 | |||||||||
| 2023-06-30 | $169.19K 10-Q · filed 2024-08-13 | $331.44K 10-Q · filed 2024-08-13 | $585.17K derived: sum of 3 quarters · filed 2024-08-13 | $681.70K derived: sum of 4 quarters · filed 2024-08-13 | |||||||||
| 2023-03-31 | $162.26K 10-Q · filed 2024-05-13 | $415.99K derived: sum of 2 quarters · filed 2024-05-13 | $512.51K derived: sum of 3 quarters · filed 2024-05-13 | $612.73K derived: sum of 4 quarters · filed 2024-05-13 | |||||||||
| 2022-12-31 | $253.73K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $350.26K derived: sum of 2 quarters · filed 2024-03-25 | $450.47K derived: sum of 3 quarters · filed 2024-03-25 | $577.65K 10-K · filed 2024-03-25 | |||||||||
| 2022-09-30 | $96.53K 10-Q · filed 2023-11-13 | $196.74K derived: sum of 2 quarters · filed 2023-11-13 | $323.92K 10-Q · filed 2023-11-13 | $496.87K derived: sum of 4 quarters · filed 2023-11-13 | |||||||||
| 2022-06-30 | $100.21K 10-Q · filed 2023-08-11 | $227.39K 10-Q · filed 2023-08-11 | $400.34K derived: sum of 3 quarters · filed 2023-08-11 | $455.28K derived: sum of 4 quarters · filed 2023-08-11 | |||||||||
| 2022-03-31 | $127.18K 10-Q · filed 2023-05-12 | $300.13K derived: sum of 2 quarters · filed 2023-05-12 | $355.07K derived: sum of 3 quarters · filed 2023-05-12 | $410.01K derived: sum of 4 quarters · filed 2023-05-12 | |||||||||
| 2021-12-31 | $172.95K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $227.89K derived: sum of 2 quarters · filed 2023-03-24 | $282.83K derived: sum of 3 quarters · filed 2023-03-24 | $395.12K 10-K · filed 2023-03-24 | |||||||||
| 2021-09-30 | $54.94K 10-Q · filed 2022-11-10 | $109.89K derived: sum of 2 quarters · filed 2022-11-10 | $222.18K 10-Q · filed 2022-11-10 | $260.97K derived: sum of 4 quarters · filed 2022-11-10 | |||||||||
| 2021-06-30 | $54.94K 10-Q · filed 2022-08-01 | $167.23K 10-Q · filed 2022-08-01 | $206.03K derived: sum of 3 quarters · filed 2022-08-01 | $243.34K derived: sum of 4 quarters · filed 2022-08-01 | |||||||||
| 2021-03-31 | $112.29K 10-Q · filed 2022-05-13 | $151.09K derived: sum of 2 quarters · filed 2022-05-13 | $188.40K derived: sum of 3 quarters · filed 2022-05-13 | $837.71K derived: sum of 4 quarters · filed 2022-05-13 | |||||||||
| 2020-12-31 | $38.80K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $76.10K derived: sum of 2 quarters · filed 2022-03-28 | $725.41K derived: sum of 3 quarters · filed 2022-03-28 | $755.99K 10-K · filed 2022-03-28 | |||||||||
| 2020-09-30 | $37.31K 10-Q · filed 2021-11-10 | $686.62K derived: sum of 2 quarters · filed 2021-11-10 | $717.20K 10-Q · filed 2021-11-10 | $833.06K derived: sum of 4 quarters · filed 2021-11-10 | |||||||||
| 2020-06-30 | $649.31K 10-Q · filed 2021-08-13 | $679.89K 10-Q · filed 2021-08-13 | $795.75K derived: sum of 3 quarters · filed 2021-08-13 | $883.24K derived: sum of 4 quarters · filed 2021-08-13 | |||||||||
| 2020-03-31 | $30.58K 10-Q · filed 2021-05-17 | $146.44K derived: sum of 2 quarters · filed 2021-05-17 | $233.93K derived: sum of 3 quarters · filed 2021-05-17 | $320.17K derived: sum of 4 quarters · filed 2021-05-17 | |||||||||
| 2019-12-31 | $115.86K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-17 | $203.35K derived: sum of 2 quarters · filed 2021-05-17 | $289.59K derived: sum of 3 quarters · filed 2021-05-17 | $319.59K 10-K/A · filed 2021-05-17 | |||||||||
| 2019-09-30 | $87.48K 10-Q · filed 2020-11-05 | $173.72K derived: sum of 2 quarters · filed 2020-11-05 | $203.72K 10-Q · filed 2020-11-05 | $233.72K derived: sum of 4 quarters · filed 2020-11-05 | |||||||||
| 2019-06-30 | $86.24K 10-Q · filed 2020-08-14 | $116.24K 10-Q · filed 2020-08-14 | $146.24K derived: sum of 3 quarters · filed 2020-08-14 | $176.24K derived: sum of 4 quarters · filed 2020-08-14 | |||||||||
| 2019-03-31 | $30.00K 10-Q · filed 2020-05-12 | $60.00K derived: sum of 2 quarters · filed 2020-05-12 | $90.00K derived: sum of 3 quarters · filed 2020-05-12 | $130.00K derived: sum of 4 quarters · filed 2020-05-12 | |||||||||
| 2018-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $60.00K derived: sum of 2 quarters · filed 2020-03-20 | $100.00K derived: sum of 3 quarters · filed 2020-03-20 | $145.00K 10-K · filed 2020-03-20 | |||||||||
| 2018-09-30 | $30.00K 10-Q · filed 2019-11-13 | $70.00K derived: sum of 2 quarters · filed 2019-11-13 | $115.00K 10-Q · filed 2019-11-13 | $157.50K derived: sum of 4 quarters · filed 2019-11-13 | |||||||||
| 2018-06-30 | $40.00K 10-Q · filed 2019-08-13 | $85.00K 10-Q · filed 2019-08-13 | $127.50K derived: sum of 3 quarters · filed 2019-08-13 | $172.50K derived: sum of 4 quarters · filed 2019-08-13 | |||||||||
| 2018-03-31 | $45.00K 10-Q · filed 2019-05-14 | $87.50K derived: sum of 2 quarters · filed 2019-05-14 | $132.50K derived: sum of 3 quarters · filed 2019-05-14 | ||||||||||
| 2017-12-31 | $42.50K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-04 | $87.50K derived: sum of 2 quarters · filed 2019-04-04 | $177.50K 10-K · filed 2019-04-04 | ||||||||||
| 2017-09-30 | $45.00K 10-Q · filed 2018-11-14 | $135.00K 10-Q · filed 2018-11-14 | |||||||||||
| 2013-09-30 | $0.00 derived: 10-Q 39 month − 10-Q 36 month · filed 2013-11-14 | $1.07M 10-Q · filed 2013-11-14 | |||||||||||
| 2013-06-30 | $1.07M 10-Q · filed 2013-08-08 | ||||||||||||
| 2013-03-31 | $1.07M 10-Q · filed 2013-05-15 | ||||||||||||
| 2012-12-31 | $1.07M 10-K · filed 2013-03-05 | ||||||||||||
| 2012-09-30 | $0.00 derived: 10-Q 27 month − 10-Q 24 month · filed 2012-11-13 | $0.00 derived: sum of 2 quarters · filed 2012-11-13 | $0.00 derived: sum of 3 quarters · filed 2012-11-13 | $0.00 derived: sum of 4 quarters · filed 2012-11-13 | $1.07M 10-Q · filed 2012-11-13 | ||||||||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | $0.00 10-Q · filed 2012-08-01 | $0.00 derived: sum of 3 quarters · filed 2012-08-01 | $0.00 derived: sum of 4 quarters · filed 2012-08-01 | $1.07M 10-Q · filed 2012-08-01 | ||||||||
| 2012-03-31 | $0.00 10-Q · filed 2012-05-15 | $0.00 derived: sum of 2 quarters · filed 2012-05-15 | $0.00 derived: sum of 3 quarters · filed 2012-05-15 | $0.00 derived: sum of 4 quarters · filed 2012-08-01 | $1.07M 10-Q · filed 2012-05-15 | ||||||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-01-26 | $0.00 derived: sum of 2 quarters · filed 2012-01-26 | $0.00 derived: sum of 3 quarters · filed 2012-08-01 | $0.00 10-K · filed 2012-01-26 | $1.07M 10-K · filed 2012-01-26 | ||||||||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10 | $0.00 derived: sum of 2 quarters · filed 2012-08-01 | $0.00 10-Q · filed 2011-11-10 | $1.07M 10-Q · filed 2011-11-10 | |||||||||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | $0.00 10-Q · filed 2012-08-01 | $1.07M 10-Q · filed 2011-08-15 | ||||||||||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-15 | ||||||||||||
| 2010-12-31 | $1.07M 10-K · filed 2012-01-26 | ||||||||||||
| 2010-09-30 | $0.00 10-Q · filed 2011-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |